Drug Trial Radar · NCT03136185
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
Last checked: Nov 19, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Jul 18, 2017
Primary completion
Mar 8, 2022
Study completion Mar 8, 2022
Sponsor
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- May 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, steady-state pharmacokinetic (PK) and pharmacodynamics (PD) of a lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat (IMG-7289/MK-3543), administered orally once daily in participants with myelofibrosis. The primary hypothesis is that bomedemstat is a safe and tolerable orally available agent when administered to participants with myelofibrosis including primary myelofibrosis (PMF), post-polycythaemia vera-myelofibrosis (PPVMF), and post-essential thrombocythaemia-myelofibrosis (PET-MF) (collectively referred to as 'MF'); inhibition of LSD1 by bomedemstat will reduce spleen size in those with splenomegaly, improve haematopoiesis and reduce constitutional symptoms associated with these disorders.
Conditions
- Myelofibrosis
- Post-polycythemia Vera Myelofibrosis (PPV-MF)
- Post-essential Thrombocythemia Myelofibrosis (PET-MF)
- Primary Myelofibrosis (PMF)
Interventions
BomedemstatDrug
Oral (capsule) administration according to dose allocation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to Day 7 of the ITP
- Number of Participants With Serious Adverse EventsTime frame: Up to approximately 30 months
- Number of Participants With Adverse EventsTime frame: Up to approximately 30 months
- Number of Participants That Discontinued Study Treatment Due To AEsTime frame: Up to approximately 29 months
- Phase 1/2a Portion: Observed Maximum Concentration (Cmax) of BomedemstatTime frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
- Phase 1/2a Portion: Time to Maximum Concentration (Tmax) of BomedemstatTime frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
- Phase 1/2a Portion: Area Under the Concentration-time Curve of Bomedemstat From Time 0 to 24 Hours Post-dose (AUC0-24)Time frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
- Phase 1/2a Portion: Apparent Total Clearance (CL/F) of Bomedemstat After Oral AdministrationTime frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
- Percentage Change From Baseline in Spleen VolumeTime frame: Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), and ATP1 Day 168 (Study Day 337)
- Percentage Change From Baseline in Spleen SizeTime frame: Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), ATP1 Day 168 (Study Day 337), ATP2 Day 84 (Study Day 422), ATP2 Day 168 (Study Day 506), and ATP3 Day 84 (Study Day 591)
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
University of Michigan
Ann Arbor, Michigan
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Universitatsklinikum Essen
Essen, Germany
Azienda Ospedaliero Universitaria Careggi
Florence, Italy
Guy's and St Thomas' Hospitals
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.